Ianalumab

Novartis · VAY736

FollowEvery change as it happens, and a Monday email
Stage
in the US · press release
Next date
Phase 3 trial completes
Trials
16 active
31 in total · 19 in the EU
Targets
 

What this is

How it works
BAFF receptor (BAFF-R) antibody
How it’s given
“VAY736 once monthly solution for injection for subcutaneous use.”In the company’s words, NCT07621809 on ClinicalTrials.gov
Tested for
Primary Immune Thrombocytopenia (ITP) (4 trials), Systemic Lupus Erythematosus (4 trials), Lupus Nephritis (2 trials), Sjogren Syndrome, Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia (wAIHA), Sjögren´s Disease, Sjogrens Syndrome and 4 more
Main trialPhase 3
“A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)”In the company’s words, NCT05349214 on ClinicalTrials.gov
Other names
VAY736

Other drugs for Primary Immune Thrombocytopenia (ITP)

All 32 drugs for Primary Immune Thrombocytopenia (ITP)

Coming up10

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials31

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 13 May 2025 Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
Phase 3Active, not recruiting 19 Jun 2025 A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
Phase 3Active, not recruiting 20 Feb 2026 A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
Phase 3Active, not recruiting 29 Oct 2026 Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Phase 3Active, not recruiting 26 Mar 2027 Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
Phase 3Active, not recruiting 12 Apr 2027 Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
Phase 3Active, not recruiting 21 Sep 2027 Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Phase 3Recruiting 15 Aug 2029 Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Phase 3Active, not recruiting 22 Apr 2033 A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
Phase 3Recruiting 3 Apr 2034 Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Phase 3Recruiting 1 Aug 2035 Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Phase 2Active, not recruiting 5 Feb 2025 A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
Phase 2Active, not recruiting 17 Feb 2026 Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
Phase 2Active, not recruiting 30 Jul 2027 A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Phase 2Recruiting 18 Jan 2029 A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Phase 2Not yet recruiting 22 Apr 2033 A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
Phase 3Completed 7 May 2025 Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
Phase 2/3Completed 28 Dec 2023 ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
Phase 2Terminated 5 May 2015 A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
Phase 2Completed 7 Feb 2018 PD of VAY736 in Patients With Primary Sjögren's Syndrome
Phase 2Terminated 25 Sep 2019 Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris
Phase 2Completed 30 Jun 2020 Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)
Phase 2Terminated 25 Nov 2020 Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
Phase 2Completed 27 Jul 2022 Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients
Phase 2Completed 26 Jun 2024 Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.
Phase 2Completed 4 Dec 2024 Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
Phase 2Withdrawn 30 Aug 2030 Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
Phase 1Terminated 29 Sep 2023 VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib
Phase 1Completed 18 Jul 2024 Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis
Phase 1Terminated 24 Feb 2025 Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Phase 1Withdrawn 17 Dec 2025 Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ianalumab

Following is part of Solo: you see every change to Ianalumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in